Establishing a Multiple myeloma disease model on a microfluidic system and investigating Bortezomib drug responses

Multiple myeloma is a hematological malignancy in which treatment efficacy is frequently limited by the development of drug resistance, particularly to bortezomib. Existing preclinical models inadequately represent the human bone marrow microenvironment, reducing their predictive value for therapeutic response. This project aims to develop a microfluidic multiple myeloma-on-chip platform incorporating bone marrow–derived cell types and extracellular matrix components to evaluate bortezomib-induced cytotoxicity and resistance under physiologically relevant conditions. The proposed system provides a rapid, cost-effective, and human-relevant tool for drug response assessment and resistance studies in multiple myeloma.

Engineering PLGA-Based Nanoparticle Platforms via Microfluidic Synthesis for Bortezomib Delivery in Multiple Myeloma

This project investigates the microfluidic synthesis and comparative evaluation of PLGA-based nanoparticles for bortezomib delivery in multiple myeloma. By leveraging the precise control offered by microfluidic platforms, the study aims to correlate nanoparticle design parameters with drug release behavior and cytotoxic efficacy, enabling the development of optimized and reproducible nanomedicine strategies.

Investigation of the Effect of Bortezomib Loaded Superparamagnetic Iron Oxide Nanoparticle (SPION) on Multiple Myeloma Cells in a Magnetically Guided Drug Delivery System

Bortezomib is the most effective chemotherapeutic used in multiple myeloma treatment, but its clinical utility is limited by systemic toxicity and the development of drug resistance. This project aims to develop a magnetically guided nanoparticle-based delivery system by loading bortezomib into superparamagnetic iron oxide nanoparticles (SPIONs) to achieve targeted delivery to myeloma cells. By reducing off-target effects and improving therapeutic localization, the proposed approach seeks to enhance treatment efficacy while minimizing adverse side effects.

Design and Development of a Variable Field Multiple Magnet System for Targeting Bortezomib-Loaded SPION Nanoparticles

Bortezomib is the most effective chemotherapeutic for multiple myeloma treatment, but its clinical use is limited by systemic toxicity and acquired drug resistance. This project aims to develop a magnetically guided drug delivery system by loading bortezomib into superparamagnetic iron oxide nanoparticles (SPIONs) and directing them to myeloma cells using a rotating magnetic actuation system. By enabling three-dimensional, localized magnetic targeting beyond superficial tumors, the proposed approach seeks to enhance therapeutic precision while minimizing off-target effects and treatment-associated toxicity.

Integrated, Scalable, Functional Nanostructures and Systems

 

Maestro – Micro Medical Technologies Platform